Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
JMP Securities biotech analyst to hold an analyst/industry conference call » 13:12
09/29/22
09/29
13:12
09/29/22
13:12
MDGL

Madrigal Pharmaceuticals

$65.75 /

-2.98 (-4.34%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Rohit Loomba, discuss getting ready for Madrigal Pharmaceuticals (MDGL) Pirvotal NASH data on an Analyst/Industry conference call to be held on October 6.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$65.75 /

-2.98 (-4.34%)

MDGL Madrigal Pharmaceuticals
$65.75 /

-2.98 (-4.34%)

09/13/22 Piper Sandler
Piper says Akero data increases conviction in Madrigal NASH readout
07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
MDGL Madrigal Pharmaceuticals
$65.75 /

-2.98 (-4.34%)

Over a week ago
Recommendations
Piper says Akero data increases conviction in Madrigal NASH readout » 10:37
09/13/22
09/13
10:37
09/13/22
10:37
MDGL

Madrigal Pharmaceuticals

$71.25 /

+0.52 (+0.74%)

, AKRO

Akero Therapeutics

$28.26 /

+15.93 (+129.20%)

After Akero Therapeutics…

After Akero Therapeutics (AKRO) reported that its 24-week HARMONY study in patients with pre-cirrhotic nonalcoholic steatohepatitis or NASH, fibrosis met its primary endpoint for both the 50mg and 28mg efruxifermin dose groups, Piper Sandler analyst Yasmeen Rahimi said that dataset increased her conviction for Madrigal Pharmaceuticals' (MDGL) upcoming resmetirom MAESTRO-NASH study that has been guided to read out topline data in Q4. The analyst, who also argues that Akero's data "does not alter the bar for success, but instead stimulates greater interest in NASH," keeps an Overweight rating and $203 price target on Madrigal shares.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$71.25 /

+0.52 (+0.74%)

AKRO Akero Therapeutics
$28.26 /

+15.93 (+129.20%)

MDGL Madrigal Pharmaceuticals
$71.25 /

+0.52 (+0.74%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
AKRO Akero Therapeutics
$28.26 /

+15.93 (+129.20%)

11/15/21 Canaccord
Searching... price target raised to $49 from $46 at Canaccord
10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
MDGL Madrigal Pharmaceuticals
$71.25 /

+0.52 (+0.74%)

AKRO Akero Therapeutics
$28.26 /

+15.93 (+129.20%)

AKRO Akero Therapeutics
$28.26 /

+15.93 (+129.20%)

Conference/Events
Cowen biotechnology analyst to hold an analyst/industry conference call » 09:45
09/08/22
09/08
09:45
09/08/22
09:45
MDGL

Madrigal Pharmaceuticals

$65.23 /

-0.88 (-1.33%)

, ICPT

Intercept

$16.79 /

-0.02 (-0.12%)

, AKRO

Akero Therapeutics

$11.91 /

-0.07 (-0.58%)

Biotechnology Analyst…

Biotechnology Analyst Baral, along with Dr. Stephen Harrison, Medical Director for Pinnacle Clinical Research, discuss NASH Rehash and upcoming trial readouts including Madrigal's THR-beta Medical Director for Pinnacle Clinical Research, Intercept's OCA, including the re-analysis of the Ph3 REGENERATE trial and other programs in the present NASH drug development landscape including Akero's Phase 2 efruxifermin on an Analyst/Industry conference call to be held on September 8 at 10 am. Webcast Link

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$65.23 /

-0.88 (-1.33%)

ICPT Intercept
$16.79 /

-0.02 (-0.12%)

AKRO Akero Therapeutics
$11.91 /

-0.07 (-0.58%)

MDGL Madrigal Pharmaceuticals
$65.23 /

-0.88 (-1.33%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
ICPT Intercept
$16.79 /

-0.02 (-0.12%)

08/22/22 B. Riley
Intercept's 'transformational' moves being underappreciated, says B. Riley
08/08/22 H.C. Wainwright
Intercept price target lowered to $16 from $18 at H.C. Wainwright
08/03/22 Piper Sandler
Piper Sandler remains bullish on Intercept into NDA resubmission of OCA
07/08/22 Needham
Intercept price target lowered to $22 from $25 at Needham
AKRO Akero Therapeutics
$11.91 /

-0.07 (-0.58%)

11/15/21 Canaccord
Searching... price target raised to $49 from $46 at Canaccord
10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
09/10/21 BofA
Akero Therapeutics initiated with a Buy at BofA
MDGL Madrigal Pharmaceuticals
$65.23 /

-0.88 (-1.33%)

ICPT Intercept
$16.79 /

-0.02 (-0.12%)

AKRO Akero Therapeutics
$11.91 /

-0.07 (-0.58%)

ICPT Intercept
$16.79 /

-0.02 (-0.12%)

AKRO Akero Therapeutics
$11.91 /

-0.07 (-0.58%)

Conference/Events
Cowen biotechnology analyst to hold an analyst/industry conference call » 04:55
09/08/22
09/08
04:55
09/08/22
04:55
MDGL

Madrigal Pharmaceuticals

$65.98 /

-0.475 (-0.71%)

, ICPT

Intercept

$16.79 /

+0.49 (+3.01%)

, AKRO

Akero Therapeutics

$11.91 /

-1.47 (-10.99%)

Biotechnology Analyst…

Biotechnology Analyst Baral, along with Dr. Stephen Harrison, Medical Director for Pinnacle Clinical Research, discuss NASH Rehash and upcoming trial readouts including Madrigal's THR-beta Medical Director for Pinnacle Clinical Research, Intercept's OCA, including the re-analysis of the Ph3 REGENERATE trial and other programs in the present NASH drug development landscape including Akero's Phase 2 efruxifermin on an Analyst/Industry conference call to be held on September 8 at 10 am. Webcast Link

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$65.98 /

-0.475 (-0.71%)

ICPT Intercept
$16.79 /

+0.49 (+3.01%)

AKRO Akero Therapeutics
$11.91 /

-1.47 (-10.99%)

MDGL Madrigal Pharmaceuticals
$65.98 /

-0.475 (-0.71%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
ICPT Intercept
$16.79 /

+0.49 (+3.01%)

08/22/22 B. Riley
Intercept's 'transformational' moves being underappreciated, says B. Riley
08/08/22 H.C. Wainwright
Intercept price target lowered to $16 from $18 at H.C. Wainwright
08/03/22 Piper Sandler
Piper Sandler remains bullish on Intercept into NDA resubmission of OCA
07/08/22 Needham
Intercept price target lowered to $22 from $25 at Needham
AKRO Akero Therapeutics
$11.91 /

-1.47 (-10.99%)

11/15/21 Canaccord
Searching... price target raised to $49 from $46 at Canaccord
10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
09/10/21 BofA
Akero Therapeutics initiated with a Buy at BofA
MDGL Madrigal Pharmaceuticals
$65.98 /

-0.475 (-0.71%)

ICPT Intercept
$16.79 /

+0.49 (+3.01%)

AKRO Akero Therapeutics
$11.91 /

-1.47 (-10.99%)

ICPT Intercept
$16.79 /

+0.49 (+3.01%)

AKRO Akero Therapeutics
$11.91 /

-1.47 (-10.99%)

Conference/Events
Jefferies biotech/pharma analyst to hold analyst/industry conference call » 09:43
09/06/22
09/06
09:43
09/06/22
09:43
MDGL

Madrigal Pharmaceuticals

$71.72 /

+0.01 (+0.01%)

Biotech/Pharmaceuticals…

Biotech/Pharmaceuticals Analyst Tewari discusses expectations for Madrigal Pharmaceuticals' Phase 3 MAESTRO-NASH read-out on an Analyst/Industry conference call to be held on September 6 at 12 pm.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$71.72 /

+0.01 (+0.01%)

MDGL Madrigal Pharmaceuticals
$71.72 /

+0.01 (+0.01%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
MDGL Madrigal Pharmaceuticals
$71.72 /

+0.01 (+0.01%)

Over a month ago
Conference/Events
Cowen biotechnology analyst to hold an analyst/industry conference call » 10:51
08/31/22
08/31
10:51
08/31/22
10:51
MDGL

Madrigal Pharmaceuticals

$68.49 /

+2.84 (+4.33%)

, ICPT

Intercept

$16.63 /

+0.345 (+2.12%)

, AKRO

Akero Therapeutics

$12.02 /

-0.355 (-2.87%)

Biotechnology Analyst…

Biotechnology Analyst Baral, along with Dr. Stephen Harrison, Medical Director for Pinnacle Clinical Research, discuss NASH Rehash and upcoming trial readouts including Madrigal's THR-beta Medical Director for Pinnacle Clinical Research, Intercept's OCA, including the re-analysis of the Ph3 REGENERATE trial and other programs in the present NASH drug development landscape including Akero's Phase 2 efruxifermin on an Analyst/Industry conference call to be held on September 8 at 10 am. Webcast Link

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$68.49 /

+2.84 (+4.33%)

ICPT Intercept
$16.63 /

+0.345 (+2.12%)

AKRO Akero Therapeutics
$12.02 /

-0.355 (-2.87%)

MDGL Madrigal Pharmaceuticals
$68.49 /

+2.84 (+4.33%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
ICPT Intercept
$16.63 /

+0.345 (+2.12%)

08/22/22 B. Riley
Intercept's 'transformational' moves being underappreciated, says B. Riley
08/08/22 H.C. Wainwright
Intercept price target lowered to $16 from $18 at H.C. Wainwright
08/03/22 Piper Sandler
Piper Sandler remains bullish on Intercept into NDA resubmission of OCA
07/08/22 Needham
Intercept price target lowered to $22 from $25 at Needham
AKRO Akero Therapeutics
$12.02 /

-0.355 (-2.87%)

11/15/21 Canaccord
Searching... price target raised to $49 from $46 at Canaccord
10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
09/10/21 BofA
Akero Therapeutics initiated with a Buy at BofA
MDGL Madrigal Pharmaceuticals
$68.49 /

+2.84 (+4.33%)

ICPT Intercept
$16.63 /

+0.345 (+2.12%)

AKRO Akero Therapeutics
$12.02 /

-0.355 (-2.87%)

ICPT Intercept
$16.63 /

+0.345 (+2.12%)

AKRO Akero Therapeutics
$12.02 /

-0.355 (-2.87%)

Hot Stocks
Madrigal Pharmaceuticals initiates MAESTRO-NASH Outcomes study » 08:16
08/31/22
08/31
08:16
08/31/22
08:16
MDGL

Madrigal Pharmaceuticals

$65.88 /

-1.5 (-2.23%)

Madrigal Pharmaceuticals…

Madrigal Pharmaceuticals announced initiation of the "MAESTRO-NASH Outcomes" study of resmetirom. MAESTRO-NASH Outcomes is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis. It is the fourth Phase 3 MAESTRO study of resmetirom, joining the MAESTRO-NAFLD-1 safety study, which reported positive data in January 2022, the ongoing MAESTRO-NAFLD Open-Label Extension study, and the pivotal MAESTRO-NASH biopsy study, which is on track for a topline data readout in Q4 2022. The primary endpoint of MAESTRO-NASH Outcomes is the incidence of composite liver-related outcome events, including all-cause mortality, liver transplant, hepatic decompensation, and confirmed increase of Model for End-Stage Liver Disease score from more than 12 to less than or equal to 15 due to progression of NASH cirrhosis. Key inclusion criteria are well-compensated NASH cirrhosis and presence of three metabolic risk factors. Patients will be randomized 3:1 in a blinded manner to receive 80 mg resmetirom or matching placebo, given orally once daily. The study duration is expected to be two to three years for accrual of the required number of composite clinical outcome events. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, "The MAESTRO-NASH Outcomes study is designed to address an urgent unmet need for patients and expand the long-term commercial opportunity for resmetirom. Positive results from this study could support full approval in the noncirrhotic population and potential for approval in an additional indication in patients with well-compensated NASH cirrhosis. Importantly, MAESTRO-NASH Outcomes does not impact the timeline for our MAESTRO-NASH biopsy study readout or initial new drug application filing in the noncirrhotic NASH population."

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$65.88 /

-1.5 (-2.23%)

MDGL Madrigal Pharmaceuticals
$65.88 /

-1.5 (-2.23%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
MDGL Madrigal Pharmaceuticals
$65.88 /

-1.5 (-2.23%)

Conference/Events
Madrigal Pharmaceuticals management to meet with Piper Sandler » 04:55
08/15/22
08/15
04:55
08/15/22
04:55
MDGL

Madrigal Pharmaceuticals

$73.39 /

+3.415 (+4.88%)

Investor Luncheon Meeting…

Investor Luncheon Meeting to be held in West Conshohocken, PA on August 15 hosted by Piper Sandler.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$73.39 /

+3.415 (+4.88%)

MDGL Madrigal Pharmaceuticals
$73.39 /

+3.415 (+4.88%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
MDGL Madrigal Pharmaceuticals
$73.39 /

+3.415 (+4.88%)

Conference/Events
Madrigal Pharmaceuticals management to meet virtually with JMP Securities » 04:55
08/11/22
08/11
04:55
08/11/22
04:55
MDGL

Madrigal Pharmaceuticals

$73.93 /

+1.44 (+1.99%)

Virtual Meeting to be…

Virtual Meeting to be held on August 11 hosted by JMP Securities.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$73.93 /

+1.44 (+1.99%)

MDGL Madrigal Pharmaceuticals
$73.93 /

+1.44 (+1.99%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
MDGL Madrigal Pharmaceuticals
$73.93 /

+1.44 (+1.99%)

Conference/Events
Madrigal Pharmaceuticals management to meet with Piper Sandler » 16:02
08/08/22
08/08
16:02
08/08/22
16:02
MDGL

Madrigal Pharmaceuticals

$77.36 /

-2.01 (-2.53%)

Investor Luncheon Meeting…

Investor Luncheon Meeting to be held in West Conshohocken, PA on August 15 hosted by Piper Sandler.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$77.36 /

-2.01 (-2.53%)

MDGL Madrigal Pharmaceuticals
$77.36 /

-2.01 (-2.53%)

07/08/22 B. Riley
B. Riley downgrades Madrigal on 'elevated uncertainty' into NASH results
07/08/22 B. Riley
Madrigal Pharmaceuticals downgraded to Neutral from Buy at B. Riley
05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
MDGL Madrigal Pharmaceuticals
$77.36 /

-2.01 (-2.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.